Vallance D T, Staunton H A, Winder A F
Department of Chemical Pathology and Human Metabolism, Royal Free Hospital School of Medicine, University of London.
J Clin Pathol. 1995 Jan;48(1):70-4. doi: 10.1136/jcp.48.1.70.
To assess whether the ability of lipoprotein related variables to discriminate between individuals with or without premature clinical ischaemic heart disease (IHD) was improved using data on high density lipoprotein-lipoprotein AI (HDL-LpAI) fractions, alone or in combination with data on Lp(a).
Lipid and apolipoprotein concentrations were measured in 26 middle-aged men (mean age 50.3 years) with early onset IHD and coronary artery bypass grafting prior to sampling, and in 26 matched lipaemic and 26 normolipaemic asymptomatic controls.
Triglyceride and Lp(a) concentrations were higher, while HDL cholesterol and apolipoprotein A-I (apoA-I) concentrations were lower in patients than in controls. LpAI concentrations were also lower in IHD patients and were correlated with HDL and apoA-I in both IHD and control groups. Lp(a) was not correlated with any other lipid or apolipoprotein measured in either patients or controls. Univariate discriminant function analysis showed that the proportion correctly classified as patients or controls was marginally greater using LpAI concentrations as the discriminator, which was not increased in combination with Lp(a). Serum triglycerides, HDL cholesterol, apoA-I and Lp(a) alone all had similar, but weaker, discriminant power, which increased in various combinations with LpAI.
LpAI particle measurement may be useful in research to define mechanisms of cardiovascular protection by HDL but the discriminating power for IHD was only marginally superior to measuring total apoA-I or Lp(a) concentrations. Little further advantage arose through combining LpAI data with other variables.
评估单独使用高密度脂蛋白 - 脂蛋白AI(HDL - LpAI)组分数据或与脂蛋白(a)[Lp(a)]数据联合使用时,脂蛋白相关变量区分有或无早发性临床缺血性心脏病(IHD)个体的能力是否得到改善。
对26名患有早发性IHD且在采样前接受冠状动脉搭桥术的中年男性(平均年龄50.3岁)、26名匹配的血脂异常者和26名血脂正常的无症状对照者测量脂质和载脂蛋白浓度。
患者的甘油三酯和Lp(a)浓度较高,而高密度脂蛋白胆固醇和载脂蛋白A - I(apoA - I)浓度低于对照组。IHD患者的LpAI浓度也较低,并且在IHD组和对照组中均与高密度脂蛋白和apoA - I相关。Lp(a)与患者或对照组中测量的任何其他脂质或载脂蛋白均无相关性。单变量判别函数分析表明,以LpAI浓度作为判别指标时,正确分类为患者或对照组的比例略高,与Lp(a)联合使用时并未增加。单独的血清甘油三酯、高密度脂蛋白胆固醇、apoA - I和Lp(a)都具有相似但较弱的判别能力,与LpAI的各种组合使用时判别能力增强。
LpAI颗粒测量在研究中可能有助于确定高密度脂蛋白对心血管的保护机制,但对IHD的判别能力仅略优于测量总apoA - I或Lp(a)浓度。将LpAI数据与其他变量联合使用几乎没有进一步的优势。